AG-221, an oral, selective, first-in-class, potent inhibitor of the IDH2 mutant metabolic enzyme, induces durable remissions in a phase I study in patients with IDH2 mutation positive advanced hematologic malignancies Meeting Abstract
| Authors: | Stein, E. M.; Altman, J. K.; Collins, R.; DeAngelo, D. J.; Fathi, A. T.; Flinn, I.; Frankel, A.; Levine, R. L.; Medeiros, B. C.; Patel, M.; Pollyea, D. A.; Roboz, G. J.; Stone, R. M.; Swords, R. T.; Tallman, M. S.; Agresta, S.; Fan, B.; Yang, H.; Yen, K.; de Botton, S. |
| Abstract Title: | AG-221, an oral, selective, first-in-class, potent inhibitor of the IDH2 mutant metabolic enzyme, induces durable remissions in a phase I study in patients with IDH2 mutation positive advanced hematologic malignancies |
| Meeting Title: | 56th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 124 |
| Issue: | 21 |
| Meeting Dates: | 2014 Dec 6-9 |
| Meeting Location: | San Francisco, CA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2014-12-06 |
| Language: | English |
| ACCESSION: | WOS:000349233806164 |
| PROVIDER: | wos |
| DOI: | 10.1182/blood.V124.21.115.115 |
| Notes: | Meeting Abstract: 115 -- 56th Annual Meeting of the American-Society-of-Hematology -- DEC 06-09, 2014 -- San Francisco, CA -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work